All locations are open for appointments and procedures, including COVID-19 testing. Schedule an appointment online or call your doctor’s office. Patients may be accompanied by visitors. Read our updated visitor policy.

If you need help accessing our website, call 855-698-9991
Skip to main content
NYU Langone Provider

William M. Gerba, MD

NYU Langone Provider
  • Specialty: Pediatric Hematology-Oncology
  • Language: English
  • Phone: 516-663-9400
View Locations

Positions
  • Clinical Assistant Professor, Department of Pediatrics at NYU Long Island School of Medicine
Board Certifications
  • American Board of Pediatrics - Pediatrics, 2009
  • American Board of Pediatrics (Pediatric Hematology-Oncology), 1980
Education and Training
  • Fellowship, New York Weill Cornell Med Ctr, Pediatric Hem/onc, 1980
  • Residency, Montefiore Medical Center, Pediatric Hem/onc, 1977

Is this your profile?

Edit profile

This provider accepts the following insurance plans.

  • Aetna
    • Aetna HMO
    • Aetna Indemnity
    • Aetna Medicare
    • Aetna POS
    • Aetna PPO/EPO
  • Cigna
    • Cigna EPO/POS
    • Cigna PPO
  • Empire Blue Cross Blue Shield
    • Empire Blue Cross Blue Shield HealthPlus
    • Empire Blue Cross Blue Shield HealthPlus Essential
  • Fidelis
    • Fidelis Child Health
    • Fidelis Essential
    • Fidelis Exchange
    • Fidelis Medicaid
    • Fidelis Medicare
  • GHI
    • GHI CBP
    • GHI HMO
  • HIP
    • HIP Access I
    • HIP Essential
    • HIP Medicaid
  • HealthSmart
    • HealthSmart (WTC)
View All Accepted Plans This list of insurances changes regularly, and insurance plans listed may not be accepted at all office locations for this provider. Before your appointment, please confirm with your insurance company that this provider accepts your insurance.

Locations and Appointments

NYU Langone Pediatric Associates - Mineola

120 Mineola Boulevard, Suite 460
Mineola, NY 11501

Phone

516-663-9400

View Map

  • A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations

    Learn More

  • AAML18P1: Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)

    Learn More

  • A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727 IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1(NF1)

    Learn More
View All Research Studies (8)